Cullinan Therapeutics, Inc. (CGEM) は上場企業です ヘルスケア セクターの Medical - Pharmaceuticals 業界で事業展開. 本社所在地は Cambridge, MA, アメリカ. 現CEOは Nadim Ahmed.
CGEM を有する IPO日 2021-01-08, 111 名の正社員, に上場 NASDAQ Global Select, 時価総額 $868.55M.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
